Search research articles
Contact Us
Filters
Showing results (11-20 of 15) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 15 results.
Autism : the International Journal of Research and Practice
|
June 25, 2025
Development of a Goal Attainment Scale (GAS) outcome measure for clinical interventional studies in paediatric autism
Hannah Staunton, Tammy McIver, Julian Tillmann, et al.
Annals of Clinical and Translational Neurology
|
October 26, 2024
Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study
Scott D Newsome, Lawrence Goldstick, Derrick S Robertson, et al.
Neurology
|
April 17, 2025
Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study
Scott D Newsome, Ewa Krzystanek, Krzysztof W Selmaj, et al.
Neurology
|
December 3, 2024
Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial
Hans-Peter Hartung, Ralph H B Benedict, Thomas Berger, et al.
Multiple Sclerosis and Related Disorders
|
November 24, 2023
Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis
Ahmed Abdelhak, Kai Antweiler, Markus C Kowarik, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 15) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 15 results.
Autism : the International Journal of Research and Practice
|
June 25, 2025
Development of a Goal Attainment Scale (GAS) outcome measure for clinical interventional studies in paediatric autism
Hannah Staunton, Tammy McIver, Julian Tillmann, et al.
Annals of Clinical and Translational Neurology
|
October 26, 2024
Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study
Scott D Newsome, Lawrence Goldstick, Derrick S Robertson, et al.
Neurology
|
April 17, 2025
Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study
Scott D Newsome, Ewa Krzystanek, Krzysztof W Selmaj, et al.
Neurology
|
December 3, 2024
Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial
Hans-Peter Hartung, Ralph H B Benedict, Thomas Berger, et al.
Multiple Sclerosis and Related Disorders
|
November 24, 2023
Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis
Ahmed Abdelhak, Kai Antweiler, Markus C Kowarik, et al.
Page
of 2